Treatment of Metastatic Cancer in Terminally Diagnosed Patients
1 other identifier
expanded_access
N/A
1 country
1
Brief Summary
The objective is to provide terminally diagnosed patients with a last line of treatment while improving overall quality of life. Tempol can be added to any chemotherapy regimen to potentially reduce side effects and overcome chemoresistance.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 30, 2022
CompletedFirst Posted
Study publicly available on registry
August 8, 2022
CompletedSeptember 1, 2022
August 1, 2022
July 30, 2022
August 31, 2022
Conditions
Interventions
Eligibility Criteria
You may qualify if:
- metastatic terminally diagnosed cancer
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
UCHealth University of Colorado Cancer Center - Anschutz Medical Campus
Aurora, Colorado, 80045, United States
Related Publications (1)
Ravizza R, Cereda E, Monti E, Gariboldi MB. The piperidine nitroxide Tempol potentiates the cytotoxic effects of temozolomide in human glioblastoma cells. Int J Oncol. 2004 Dec;25(6):1817-22.
PMID: 15547722BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 30, 2022
First Posted
August 8, 2022
Last Updated
September 1, 2022
Record last verified: 2022-08